8-K: Penumbra, Inc. Announces Retirement of Don Kassing from Board of Directors

Don Kassing will retire from Penumbra's Board of Directors effective April 1, 2025, after 17 years of service.

Summary

• Penumbra, Inc. announced that Don Kassing will retire from its Board of Directors effective April 1, 2025.
• Kassing has served on the board for 17 years, joining in 2008 and serving as Presiding Director since 2015.
• Adam Elsesser, board chair, president and chief executive officer of Penumbra, expressed gratitude for Kassing's contributions, wisdom, and guidance.
• Kassing's career includes roles as President Emeritus of San Jose State University, President of San Jose State University, and Vice President, Administration and Finance and Chief Financial Officer.
• He also has experience in private industry, including roles at Caleres, Inc. and General Motors Corporation.
• Penumbra is a thrombectomy company focused on developing technologies for medical conditions such as ischemic stroke and venous thromboembolism.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The announcement is about a board member's retirement, which is a normal business event. The tone is appreciative of the retiring member's contributions.

Positives

• Penumbra acknowledges Don Kassing's significant contributions and leadership during his 17-year tenure on the board.
• The company highlights Kassing's wisdom and guidance in complex situations and through phases of growth.
• Penumbra is recognized as the world's leading thrombectomy company, indicating a strong market position.

Future Outlook

The document does not contain specific forward-looking statements regarding Penumbra's financial performance or future business prospects.

Management Comments

• Adam Elsesser, board chair, president and chief executive officer of Penumbra, stated, 'We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth.'
• Elsesser also thanked Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years.

Industry Context

Penumbra operates in the medical device industry, specifically focusing on thrombectomy solutions. The retirement of a long-standing board member is a corporate governance event that may be of interest to investors and industry observers.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards as it is a specific event related to board member retirement.
• However, the announcement is in line with standard corporate governance practices for disclosing changes in board composition.
• Other medical device companies such as Medtronic, Boston Scientific, and Abbott Laboratories also regularly announce changes to their boards of directors.

Management Changes

Stakeholder Impact

• Shareholders may be interested in the change in board composition.
• Employees may be affected by the change in leadership at the board level.
• The retirement of a long-standing board member could potentially impact the company's strategic direction.

Key Dates